Last updated: 2026-09-09 04:29:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Maze Therapeutics, Inc. (MAZE) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $26.37, with a market capitalization of $1.46B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $14.75 to $53.65. This page covers its latest market performance, valuation, price trends and company information.
$1.46B | |
$25.76 | |
$53.65 | |
$6.71 | |
$26.21 | |
292.02K | |
547.40K | |
-- | |
$53.65 | |
$14.75 | |
-- | |
-- |
Maze Therapeutics, Inc. (MAZE) last closed at $26.21 as of 2026-09-08 23:31:00, unchanged from the previous close of $26.21.
During the latest regular trading session, MAZE traded between $6.71 and $53.65, with a volume of 292.02K shares. The closing price was near the middle and near the lower end of its 52-week range.
Over the past seven days, Maze Therapeutics, Inc. (MAZE) moved from $28.60 to $26.37, representing a decline of 7.79% ($2.23).
The stock traded between $25.62 and $29.01 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 422.03 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 29.9%
MAZE is currently trading at $26.37, placing it 29.9% of the way from its 52-week low of $14.75 to its 52-week high of $53.65. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 141 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Maze Therapeutics, Inc. (MAZE) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.